Background and aim: Ulcerative Colitis (UC) and Crohn’s disease (CD) are the most common forms of Inflammatory Bowel Diseases (IBD) while Aspecific Chronic Colitis (ACC) and Indeterminate Colitis (IC) are less frequent. IBD are frequently complicated by joint involvement (peripheral and axial arthritis). Antibodies recognizing cyclic citrullinated peptides (anti-CCP) are directed to proteins that contain the unusual amino acid citrulline. The anti-CCP ELISA test has an excellent specificity for the diagnosis of Rheumatoid Arthritis (RA), especially in patients with early disease, and it is considered a disease activity predictor. Anti-CCP positivity is detected also in Psoriatic Arthritis (PA) but associated with symmetrical polyarthritis pattern. Correlation between IBD, with or without arthritic manifestations, and anti-CCP positivity was not founded. The aim of our study was to evaluate the role of anti-CCP in IBD patients with arthritic manifestations (Enteropathic Arthritis, EA), with arthritic manifestations and Psoriasis (EA + Ps) and in IBD patients without extraintestinal manifestations. Material and methods: A total of 54 consecutive adult patients with IBD (24: 19 UC, 3 CD and 2 ACC), with EA (16:10 UC, 5 CD and 1 IC) and with EA + Ps (14:6 UC, 7 CD and 1 ACC) were evaluated. Anti-CCP antibodies were detected on patients serum samples by a second generation ELISA test (VCP-IgG Kit; ASTRA Srl Milano) and as positive results were defined values > 25 U/mL. Results: Anti-CCP positivity was detected in 8 of 54 patients (15%): 4 IBD (3 UC and 1 ACC), 2 EA (2 UC) and 2 EA + Ps (1 UC and 1 ACC). No significant difference (p>0.05) of the prevalence of anti-CCP was found among patients with EA, patients with EA + PS and IBD patients without arthritic manifestations and also among the three groups with different articular involvement. Instead, UC patients had significantly higher prevalence (p<0.05) of anti-CCP positivity compared with the other three subgroups. Conclusions: These preliminary results, even though on a small sample of patients, suggested that anti-CCP positivity is not related with arthritic manifestations in IBD patients, but seems to be a marker of differentiation between the various subtypes of IBD to add to the others markers already known. # L. Inflammatory bowel diseases 3. Ulcerative colitis P.170
PREVALENCE OF ANTIBODIES RECOGNAIZING CYCLIC CITRULLINATED PEPTIDE(anti CCP) IN PATIENTS WITH ULCERATIVE COLITIS
TIRRI, Rosella;VALENTINI, Gabriele;RIEGLER, Gabriele
2009
Abstract
Background and aim: Ulcerative Colitis (UC) and Crohn’s disease (CD) are the most common forms of Inflammatory Bowel Diseases (IBD) while Aspecific Chronic Colitis (ACC) and Indeterminate Colitis (IC) are less frequent. IBD are frequently complicated by joint involvement (peripheral and axial arthritis). Antibodies recognizing cyclic citrullinated peptides (anti-CCP) are directed to proteins that contain the unusual amino acid citrulline. The anti-CCP ELISA test has an excellent specificity for the diagnosis of Rheumatoid Arthritis (RA), especially in patients with early disease, and it is considered a disease activity predictor. Anti-CCP positivity is detected also in Psoriatic Arthritis (PA) but associated with symmetrical polyarthritis pattern. Correlation between IBD, with or without arthritic manifestations, and anti-CCP positivity was not founded. The aim of our study was to evaluate the role of anti-CCP in IBD patients with arthritic manifestations (Enteropathic Arthritis, EA), with arthritic manifestations and Psoriasis (EA + Ps) and in IBD patients without extraintestinal manifestations. Material and methods: A total of 54 consecutive adult patients with IBD (24: 19 UC, 3 CD and 2 ACC), with EA (16:10 UC, 5 CD and 1 IC) and with EA + Ps (14:6 UC, 7 CD and 1 ACC) were evaluated. Anti-CCP antibodies were detected on patients serum samples by a second generation ELISA test (VCP-IgG Kit; ASTRA Srl Milano) and as positive results were defined values > 25 U/mL. Results: Anti-CCP positivity was detected in 8 of 54 patients (15%): 4 IBD (3 UC and 1 ACC), 2 EA (2 UC) and 2 EA + Ps (1 UC and 1 ACC). No significant difference (p>0.05) of the prevalence of anti-CCP was found among patients with EA, patients with EA + PS and IBD patients without arthritic manifestations and also among the three groups with different articular involvement. Instead, UC patients had significantly higher prevalence (p<0.05) of anti-CCP positivity compared with the other three subgroups. Conclusions: These preliminary results, even though on a small sample of patients, suggested that anti-CCP positivity is not related with arthritic manifestations in IBD patients, but seems to be a marker of differentiation between the various subtypes of IBD to add to the others markers already known. # L. Inflammatory bowel diseases 3. Ulcerative colitis P.170I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
